Development and clinical trials of a new Software ENgine for the Assessment & optimization of drug and non-drug Therapy in Older peRsons

EU-funded SENATOR project develops new software engine for the assessment and optimisation of drug and non-drug therapy in older persons

Optimising Therapy for the Older Population with multi-morbidity

SENATOR is an ambitious EU-funded project which focuses on optimising pharmacological and non-pharmacological therapy for the multi-morbid older population under clinical care. This project refers to the FP7 Health call “Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases” under topic “Active and Healthy Ageing”.

The main purpose of the project is to develop a highly-powered and efficient software engine (SENATOR). SENATOR will be capable of individually screening the clinical status and pharmacological and non- pharmacological therapy of older people with multi-morbidity in order to define optimal drug therapy, highlight ADR risk, indicate best value drug brand for selection and provide advice on appropriate non-pharmacological therapy.

In the second phase of the project a controlled randomised multicenter clinical trial for older people with multi-morbidity and acute illnesses that are treated in hospital by specialists (other than geriatricians and clinical pharmacologists) will be performed. The clinical trial will be used to test the efficiency of SENATOR for reducing adverse drug reaction incidence, inappropriate prescribing and healthcare costs in this age group.

Keymessages:

  • SENATOR develops a highly-powered and efficient software engine to screen individually the clinical status and pharmacological and non- pharmacological therapy of older people with multi-morbidity.
  • SENATOR software defines optimal drug therapy, highlights ADR risk, indicates best value drug brand for selection and provides advice on appropriate non-pharmacological therapy

Keywords:

  • pharmacological and non- pharmacological therapy of older people
  • Multi-morbidity
  • Adverse drug reactions
  • Individually Screening